8,774,232 Shares of HighTide Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-JUN-2024.
June 18, 2024
Share
8,774,232 Shares of HighTide Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-JUN-2024. These Shares will be under lockup for 180 days starting from 21-DEC-2023 to 18-JUN-2024.
Details:
The shares held by the Pre-IPO Investors and the Founder BVI, being 53,313,484 shares ( including the Shares held by Greaty Investment, ZT Global Energy, Orient Champion and all other Pre-IPO Investors, but excluding the 18,000,000 (108,000,000 as adjusted after the Capitalization Issue) ordinary Shares held by Hepalink Biotechnology II Limited, which will be subject to lock-up for five months commencing from the Listing Date) will be subject to lock-up for a period of six months commencing from the Listing date.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Companyâs core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.